MeiraGTx Holdings plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company focused on developing novel gene therapies for rare and prevalent diseases in ophthalmology, salivary gland disorders, neurodegenerative conditions, and metabolic diseases. Founded in 2015 and headquartered in New York, New York, with additional manufacturing facilities in the United Kingdom and Ireland, the company advances a broad pipeline supported by proprietary viral vector optimization, end-to-end GMP manufacturing capabilities, and riboswitch gene regulation technology for precise, dose-responsive control of gene expression via oral small molecules. Core programs include AAV-AQP1 for radiation-induced xerostomia (Phase 3-ready) and Sjogren’s disease (preclinical); AAV-GAD for Parkinson’s disease (Phase 3-ready, with FDA RMAT designation); botaretigene sparoparvovec (AAV-RPGR) for X-linked retinitis pigmentosa (Phase 3 completed, subject to asset purchase agreement with Janssen); AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4 (specials license in the UK, pursuing expedited approvals); preclinical ophthalmology candidates such as AAV-RDH12 for RDH12-associated retinal dystrophy, AAV-ABCA4 for Stargardt’s disease, AAV-VEGFR2 for wet AMD, and undisclosed programs for dry AMD/GA and Bardet-Biedl syndrome; riboswitch-regulated therapies including RiboLeptin for lipodystrophies, undisclosed candidates for intractable neuropathic pain and GLP-1/GIP combinations for obesity/MASH/metabolic disease, and Ribo-CAR-T for oncology and autoimmune diseases; as well as AAV-BDNF for MC4R/BDNF genetic obesity and preclinical neurodegenerative programs like AAV-UPF1/AAV-CNTFR for ALS. Geographically, MeiraGTx operates primarily in the United States, United Kingdom, and European Union, targeting patients with serious unmet needs in these therapeutic areas. Recent developments include a March 2025 strategic collaboration with Hologen AI featuring a $200 million upfront payment and formation of Hologen Neuro AI Ltd joint venture with up to $230 million committed capital to accelerate Phase 3 development of AAV-GAD for Parkinson’s disease, industrialize manufacturing, and advance CNS programs; FDA RMAT designations for AAV-GAD (May 2025) and AAV2-hAQP1 for xerostomia (January 2025); publication of landmark efficacy data in The Lancet for AAV-AIPL1 restoring vision in 11 children blind from birth (February 2025), prompting MAA filing in the UK and U.S. discussions; alignment with FDA on the pivotal Phase 2 AQUAx2 study for xerostomia (2025); an asset purchase agreement with Janssen for up to $415 million covering botaretigene sparoparvovec (announced earlier); and multiple Rare Pediatric Disease Designations for inherited retinal programs.
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
MeiraGTx: Turning Dry Mouth Into Liquid Gold
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts